Nautilus Biotechnology (NAUT) EBITDA (2020 - 2026)
Nautilus Biotechnology (NAUT) posted EBITDA of -$15.8 million for Q2 2026, up 7.8% sequentially from -$17.1 million in Q2 2025, and up 7.8% YoY from -$14.6 million in Q2 2025.
Nautilus Biotechnology (NAUT) EBITDA (2020 - 2026) Analysis & Trends
Nautilus Biotechnology has reported EBITDA for 4 years, with the latest figure at -$15.8 million in Q2 2026.
- Quarterly EBITDA rose 7.8% year-over-year to -$15.8 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$35.2 million (down 79.31% YoY) and the FY2020 annual result came in at -$576035.0, changed N/A from the prior year.
- EBITDA rose to -$15.8 million in Q2 2026 per NAUT's latest filing, from -$17.1 million in the prior quarter.
- Over five years, EBITDA peaked at -$15.8 million in Q2 2026 and troughed at -$17.1 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.94 Bn | 132.09 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.59 Bn | 78.60 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 65.67 Bn | 60.49 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 57.81 Bn | 52.67 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 42.25 Bn | 37.15 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.76 Bn | 28.45 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 28.41 Bn | 10.02 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.24 Bn | 26.41 Bn | - | 133.12 Mn |
| 10 | Nautilus Biotechnology | 122.05 Mn | 122.05 Mn | 175,000.00 | -15.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -15.76 Mn |
| Jun 30, 2025 | -17.10 Mn |
| Mar 31, 2021 | -1.78 Mn |
| Dec 31, 2020 | -576,035.00 |
| Sep 30, 2020 | -186,388.00 |